GlaxoSmithKline starts using Apple's ResearchKit for a rheumatoid arthritis study, becoming the first drugmaker to use the framework for clinical research
Context & Ripple Effects
This closes a loop that opened sixteen months earlier: Apple launched ResearchKit in March 2015 as an open framework for medical researchers, and by July 2015 both GlaxoSmithKline and Purdue Pharma were weighing it for drug R&D. A mid-2015 expansion took the first study apps beyond the US to the UK and Hong Kong.
GSK moving from consideration to an actual rheumatoid arthritis clinical study makes it the first drugmaker to run regulated clinical research on the framework — the step that separates ResearchKit from academic wellness apps and puts it inside pharma's trial pipeline.
First-order effects
- GSK gains a smartphone-based recruitment and data-collection channel for its RA study, testing whether app participation can lower the cost and friction of traditional trial enrollment.
- Apple gets its first pharmaceutical validation of ResearchKit, converting a research-adjacent tool into evidence for its health-platform ambitions.
Second-order effects
- Purdue Pharma, already reported as evaluating the framework, faces pressure to move from evaluation to deployment or cede first-mover credibility to GSK.
- Rival drugmakers must now weigh app-based trials against their own enrollment models, and Apple gains leverage in health partnerships with an industry it had only courted indirectly.
Third-order effects
- If GSK's study holds up under regulatory scrutiny, phone-mediated data collection could become a recognized component of clinical-trial design, shifting trial economics toward consumer devices and forcing regulators to formalize standards for app-sourced endpoints.
The trend: Clinical research is migrating from clinic-bound enrollment toward smartphone platforms, with Apple's ResearchKit turning consumer hardware into regulated trial infrastructure.